The Asia-Pacific oncolytic virus therapy market is estimated to grow at a CAGR of more than 14% during the forecast period. The Asia-Pacific region is estimated to be a potential market for oncolytic virus therapies due growing aging population coupled with increasing prevalence and incidence of cancer across the major economies of the region. Moreover, increasing healthcare expenditure and infrastructure, and research on novel therapies for the treatment of the cancer are further supporting the market growth of the region.

Visit for Global Oncolytic Virus Therapy Market Report at: https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market

Furthermore, one of the factors surging the prevalence of cancer is the aging population. Aging weakens the immune system of the body; thereby, increasing the chances of development of chronic diseases such as cancer. With the age dynamics, cancer cases in Asia-Pacific are expected to grow, thereby driving the demand for novel cancer therapies such as oncolytic virus therapies.

The global oncolytic virus therapy market in Asia-Pacific is segmented into India, China, Japan and Rest of Asia-Pacific. China held the highest market share in the Asia-Pacific market. The market in China is growing at a CAGR of 14.5%. The market growth in China is attributed to the increasing prevalence of cancer that has encouraged the researchers and scientists in China to work on the development of novel therapies for the treatment of cancer. Moreover, significant activities have been witnessed in the Chinese oncolytic virus therapies market in recent years. For instance, in 2018, Transgene SA signed a series of agreements with Tasly Biopharmaceuticals Co. Ltd. for the development of two immunotherapies, T601 and T101, by the Transgene-Tasly joint venture in China.

Further, the Asia-Pacific oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share in 2018. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

The report covers the analysis of market players such as Oncolys BioPharma Inc., Otsuka Pharmaceuticals Co. Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Takara Bio Inc., and Viralytics Ltd operating in the Asia-Pacific oncolytic virus therapy market. Oncolys BioPharma Inc has collaborated with Okayama University (Japan) and Medigen Biotechnology Corp. (Taiwan) for the R&D of oncolytic viruses which is named under telomelysin or OBP-301 by the company. This innovative project allows the company to expand its footprint in the global market of oncolytic viruses.

Research Methodology

The market study of the Asia-Pacific oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Authentic public databases such as the WHO, World Bank, and the National Institutes of Health.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for pharmaceutical and biopharmaceutical companies, healthcare organizations, research institutes and academics, investing companies, potential investors, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Asia-Pacific Oncolytic Virus Therapy Market Research and Analysis by Product

2. Asia-Pacific Oncolytic Virus Therapy Market Research and Analysis by Application